Shares of Roche Holding AG (OTCMKTS:RHHBY – Get Rating) have been given an average recommendation of “Buy” by the twelve brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, four have issued a hold recommendation, five have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $292.67.
Several research analysts recently weighed in on the company. JPMorgan Chase & Co. dropped their target price on Roche from CHF 390 to CHF 370 and set a “neutral” rating on the stock in a research note on Friday, March 11th. Citigroup assumed coverage on Roche in a research note on Wednesday, December 22nd. They set a “buy” rating on the stock. Barclays boosted their price target on Roche from CHF 415 to CHF 450 in a research note on Thursday, April 14th. UBS Group downgraded Roche from a “neutral” rating to a “sell” rating in a research note on Tuesday. Finally, Zacks Investment Research upgraded Roche from a “hold” rating to a “strong-buy” rating and set a $58.00 price target on the stock in a research note on Wednesday, January 19th.
Shares of RHHBY stock opened at $49.15 on Thursday. Roche has a 1-year low of $40.59 and a 1-year high of $53.86. The stock’s fifty day moving average price is $48.84 and its 200 day moving average price is $49.25. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.73 and a current ratio of 0.93.
A number of large investors have recently bought and sold shares of RHHBY. Sofinnova Investments Inc. purchased a new stake in Roche during the 4th quarter worth approximately $70,764,000. Fisher Asset Management LLC grew its position in shares of Roche by 29.6% in the fourth quarter. Fisher Asset Management LLC now owns 4,658,515 shares of the company’s stock valued at $242,282,000 after purchasing an additional 1,064,621 shares in the last quarter. Cardinal Capital Management Inc. purchased a new stake in shares of Roche in the first quarter valued at approximately $18,402,000. NorthCrest Asset Manangement LLC purchased a new stake in shares of Roche in the fourth quarter valued at approximately $9,750,000. Finally, Alan B. Lancz & Associates Inc. purchased a new stake in shares of Roche in the fourth quarter valued at approximately $4,848,000. Institutional investors own 0.18% of the company’s stock.
Roche Company Profile (Get Rating)
Roche Holding AG engages in the prescription pharmaceuticals and diagnostics businesses in Switzerland, Germany, and internationally. The company offers pharmaceutical products for treating oncology, neuroscience, infectious, immunology, cardiovascular and metabolism, ophthalmology, and respiratory, as well as anemia, cancer, dermatology, hemophilia, inflammatory and autoimmune, neurological, and transplantation.
- Get a free copy of the StockNews.com research report on Roche (RHHBY)
- Google Upgraded Ahead Of Earnings
- Highly Valued Abbot Laboratories Could Move Lower
- Baker Hughes, Another Buy-The-Dip Opportunity In Oilfield Services
- Netflix (NASDAQ: NFLX) Falls Back to 2018 Levels
- Is Turning Point Therapeutics Stock at a Turning Point?
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.